DelveInsight has launched a new report on “Heart Failure – Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Heart Failure – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Heart Failure, historical and forecasted epidemiology as well as the Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Heart Failure Market Report:
As per the DelveInsight analysis, the total diagnosed prevalent cases of Heart Failure in 7MM were found to be 12,026,384 in 2017.
Among 7MM, the US reported the highest number of prevalent cases of with 6,192,189 cases in 2017.
According to DelveInsight, it is estimated that the Gender-specific prevalent cases of Heart Failure in France were 652,877 in males and 453,694 in females in 2017 respectively.
As per the DelveInsight analysis, the total prevalent cases of HF in Italy was found to be 1,472,505 cases in 2017.
In 2017, the NYHA class-specific diagnosed prevalent cases in Japan as per the class I, class II, class III, and class IV cases were estimated to be 120,902, 328,956, 311,867, and 92,706 cases.
Key benefits of the report:
Heart Failure market report covers a descriptive overview and comprehensive insight of the Heart Failure Epidemiology and Heart Failure market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Heart Failure market report provides insights on the current and emerging therapies.
Heart Failure market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Heart Failure market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Heart Failure market.
Got queries? Click here to know more about the Heart Failure Market Landscape.
Heart Failure Overview
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is corpulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle.
Heart Failure Market
The dynamics of the Heart Failure market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Empagliflozin ((Boehringer Ingelheim/Eli Lilly and Company), Vericiguat (Merck Sharp & Dohme Corp/Bayer), AZD4831 (AstraZeneca), Dapagliflozin (AstraZeneca), Omecamtiv mecarbil (Amgen), and others during the forecasted period 2019-2032.
Heart Failure Pipeline Therapies and Key Companies
Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
Vericiguat: Merck Sharp & Dohme Corp/Bayer
Omecamtiv mecarbil: Amgen
Heart Failure Market Drivers
Research and development strategies
Rising prevalence of the disease
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Heart Failure Patient Share (%) Overview at a Glance
5. Heart Failure Market Overview at a Glance
6. Heart Failure Disease Background and Overview
7. Heart Failure Epidemiology and Patient Population
8. Country-Specific Patient Population of Heart Failure
9. Heart Failure Current Treatment and Medical Practices
10. Unmet Needs
11. Heart Failure Emerging Therapies
12. Heart Failure Market Outlook
13. Country-Wise Heart Failure Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Heart Failure Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Heart Failure Market Outlook 2032.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States